Michel Lagarde
  • E-mail :[email]
  • Phone : +33472438240
  • Location : Villeurbanne, France
Last update 2021-09-17 11:45:54.042

Michel Lagarde University Professor Emeritus at INSA-Lyon (Université de Lyon)

Course and current status

Doctorate in Biochemistry (1974), Doctorate es-Sciences (1979), Doctorate in Human Biology (1983) from Claude Bernard University, Lyon.

Post-doc London (1980), Short sabbaticals: London (1981-1983), Chicago (1984), Michigan State Univ (1993), Univ California San Diego (2006).

Research Assistant at Pasteur Institute (1972-1976), Research Scientist at INSERM (1976-1987), University Professor (1987-).

Head of an INSERM Unit (1988-2006).

Founder of the Institute for Multidisciplinary Biochemistry of Lipids (IMBL) and President of the Board (2002-2012), Honorary President of IMBL since 2013.

Scientific Director of the LISA Carnot institute (2007-2012).

Scientific Director of the IBiSA Functional Lipidomics platform (2006-2014).

Vice-President of INSA-Lyon (2011-2014).

Founder and president of the Spin Off LipTher (2015-2020).

President of GERLI (1994-2001), of ICBL (2006-2009), of ISSFAL (2006-2009).

President of the International Scientific Advisory Board of the LipSTIC Labex (2020-)

Normann Medal (2008), Chevreul Medal (2010), European Lipid Science Award (ELSA) (2016), ISSFAL Fellow (2016), De Lancey et de la Hanty Award (2019).

Member of the "Académie des Sciences, Belles-Lettres et Arts de Lyon" (since 2014), and president 2020.

Member of the New York Academy of Sciences.

Scientific summary

Research interest in lipid mediators such as prostanoids and lipoxygenase products from various polyunsaturated fatty acids (PUFA) of nutritional value, especially omega-3 PUFA; their biosynthesis and biological activities in blood and vascular cells.

Lipid peroxidation associated with aging and diabetes in the frame of vascular diseases. Metabolic fate of PUFA (esterification into complex lipids and oxygenation) in humans and human cells in vitro. Biological activities of oxygenated derivatives from PUFA. Imaging of membrane lipids. Fluxolipidomics.

Targeting tissues, especially the brain, with PUFA-containing structured phospholipids. Application to neurodegenerative diseases.

More than 400 publications according to PubMed (H factor: 53) and 9 patents. 

Image d’exemple